· GluCurve is the world’s first continuous glucose monitor (CGM) for diabetic dogs and cats
· GluCurve eliminates need for manual, costly and cumbersome “glucose curves” that are today’s standard of care
· 2017 AVMA Report shows between 28,000-32,000 veterinary practices in U.S.
· 97% of DVM survey respondents indicated they’d use a pet CGM system to diagnose and manage diabetic dogs and cats as soon as available
SINGAPORE, Oct 22 (Bernama-GLOBE NEWSWIRE) — ALR Technologies (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, is pleased to release select results from comprehensive market research conducted by the consulting firm SmartPharma, evaluating the current approach to diabetes diagnosis, glucose monitoring and insulin treatment in cats and dogs. The conclusions speak strongly about the market demand for innovation to modernize the arcane standard of care today, which ALRT interprets as highly favorable for introducing the GluCurve™ Pet CGM (continuous glucose monitoring) as a simple, accurate, reliable and pain-free system to treat the approximately 4.5 million diabetic dogs and cats worldwide.
- Africa aims for greater influence in global economic policies at G20
- Syrian Authorities, Local Leaders Reach Deal To End Sectarian Clashes Near Damascus
- Lebanese President Reaffirms Commitment To Reforms, Urges U.S. Pressure On Israel To Withdraw
- Over 72,000 migrants dead, disappeared globally since 2014: UN
- Feature: Gazan Farmers Suffer Huge Losses As War Destroys Farmland
- Tajikistan, OSCE Discussed Cooperation Plans
- Australia’s Opposition Leader Says Coalition Can Win General Elections
- 21 Terrorists Killed In Western Mali: Army
- Trump’s Approval Rating Hits Lowest Level In 80 Years
- Iran Says Uranium Enrichment, Sanctions Relief Non-Negotiable Demands In Talks With U.S.